SavedAdd your journal

Journals / Güncel Retina Dergisi / 2018 / Cilt: 2 - Sayı: 4

Interferons in the Treatment of Behçet Uveitis

Behçet Hastalığına Bağlı Üveitin Tedavisinde İnterferonlar

HİLAL ESER ÖZTÜRK
YÜKSEL SÜLLÜ
Pages
352–357
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this review is to summarize the mechanism of action and the effectivity and safety of interferons in the treatment of Behçet uveitis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Behçet disease is a multisystem vasculitis with unknown etiology.
📊
Key Findings & Data:Ocular involvement, especially posterior segment involvement is the most devastating manifestation of the disease and is absolute indication for immunosuppressive treatment.
💡
Conclusion & Impact:The aim of this review is to summarize the mechanism of action and the effectivity and safety of interferons in the treatment of Behçet uveitis.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Behçet disease is a multisystem vasculitis with unknown etiology. Ocular involvement, especially posterior segment involvement is the most devastating manifestation of the disease and is absolute indication for immunosuppressive treatment. However, immunosuppression with conventional agents may be inadequate to prevent destructive uveitis attacks and consequently visual loss. Interferons that constitute the next step of the treatment are the cytokines, which have antiviral, antiproliferative, and imunomodulatory features. They are quite effective in the treatment of Behçet uveitis. They prevent recurrent attacks and improve visual prognosis. They are used successfully in the treatment of macular edema and retinal neovascularizations. Furthermore they provide long-term remission after secession of interferon treatment. The aim of this review is to summarize the mechanism of action and the effectivity and safety of interferons in the treatment of Behçet uveitis.

Özet

Behçet hastalığı etiyolojisi tam olarak bilinmeyen multisistemik bir vaskülittir. Göz tutulumu, özellikle de posterior segment tutulumu hastalığın en yıkıcı klinik görünümüdür ve mutlak immünsüpresif tedavi endikasyonudur. Ancak konvansiyonel ajanlarla yapılan immünsüpresyon üveit ataklarını ve dolayısıyla görme kaybını önlemede yetersiz olabilmektedir. Tedavinin bir sonraki basamağını oluşturan interferonlar, antiviral, antiproliferatif ve immünmodülatör özelliklere sahip olan sitokinlerdir. Behçet hastalığının göz tutulumunda oldukça etkilidirler. Tekrarlayan atakları önler ve görme prognozunu iyileştirirler. Maküler ödem ve retinal neovaskülarizasyonların tedavisinde başarıyla kullanılmaktadırlar. Ayrıca ilaç kesildikten sonra uzun dönemde remisyon sağlamaktadırlar. Bu derlemenin amacı interferonların etki mekanizmasını ve Behçet üveitinin tedavisinde etkinliği ve güvenilirliğini özetlemektir.

🔖

Cite This Article

ÖZTÜRK, H. E., SÜLLÜ, Y. (2018). Interferons in the Treatment of Behçet Uveitis. Güncel Retina Dergisi, Cilt: 2 - Sayı: 4, 352–357. https://ajindex.com/articles/212515

References (12)

  1. Zierhut M, Abu El-Asrar AM, Bodaghi B, et al. Therapy of ocular Behcet disease. Ocul Immunol Inflamm. 2014;22(1):64-76. Tugal-Tutkun I. Imaging in the diagnosis and management of Behcet disease. Int Ophthalmol Clin. 2012;52(4):183-90.
  2. Tugal-Tutkun I, Ozdal PC, Oray M, et al. Review for Diagnostics of the Year: Multimodal Imaging in Behcet Uveitis. Ocul Immunol Inflamm. 2017;25(1):7-19.
  3. Hazirolan D, Stubiger N, Pleyer U. Light on the horizont: biologicals in Behcet uveitis. Acta Ophthalmol. 2013;91(4):297-306.
  4. Tsambaos D, Eichelberg D, Goos M. Behcet’s syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res. 1986;278(4):335- 6. Kotter I, Gunaydin I, Zierhut M, et al. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum. 2004;33(5):320-35.
  5. Mesquida M, Molins B, Llorenc V, et al. Current and future treatments for Behcet’s uveitis: road to remission. Int Ophthalmol. 2014;34(2):365-81.
  6. Mackensen F, Max R, Becker MD. Interferon therapy for ocular disease. Curr Opin Ophthalmol. 2006;17(6):567-73.
  7. Liu X, Yang P, Wang C, et al. IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet’s disease. Rheumatology (Oxford). 2011;50(2):293-8.
  8. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon- alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1692-5.
  9. Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87(4):423-31. 1Deuter CM, Zierhut M, Mohle A, et al. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet’s disease. Arthritis Rheum. 2010;62(9):2796-805.
  10. Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol. 2011;129(3):288-94.
  11. Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol. 2008;146(6):837-44 e1. Diwo E, Gueudry J, Saadoun D, et al. Long-term Efficacy of Interferon in Severe Uveitis Associated with Behcet Disease. Ocul Immunol Inflamm. 2017;25(1):76-84.
  12. Kotter I, Zierhut M, Eckstein A, et al. Human recombinant interferon- alpha2a (rhIFN alpha2a) for the treatment of Behcet’s disease with si